Document Detail


High activity iodine-125 interstitial implant for gliomas.
MedLine Citation:
PMID:  1429079     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A total of 307 adult patients with glioma were treated with high-activity removable iodine-125 interstitial brain implants at the University of California at San Francisco from December 1979 to June 1990. Recurrent gliomas underwent brain implant alone whereas previously untreated (primary) tumors underwent brain implant boost after external beam radiotherapy. Of these patients, 106 had primary glioblastoma multiforme, 68 had primary non-glioblastoma glioma, 66 had recurrent glioblastoma multiforme and 67 had recurrent nonglioblastoma glioma. Median follow-up for living patients was 143 weeks. Median survival from diagnosis for primary glioblastoma multiforme and high and low grade nonglioblastoma glioma was 88 weeks, 142 weeks, and 226 weeks, respectively. Median survival measured from the date of implant for recurrent glioblastoma multiforme and high and low grade nonglioblastoma glioma was 49 weeks, 52 weeks, and 81 weeks, respectively. Ninety-two percent of patients had no toxicity or transient acute side effects. Severe acute toxicity was seen in 6% of patients, life threatening acute toxicity in 1% of patients, and fatal toxicity in less than 1% of patients. Forty percent of patients with malignant glioma underwent reoperation at a median of 33 weeks after brain implant, with tumor found in 95% of specimens at reoperation. This large experience demonstrates that interstitial implant is well-tolerated and prolongs survival in patients with primary and recurrent glioblastoma multiforme, as evidenced by the 3-year survival rates of 22% and 15%, respectively.
Authors:
C O Scharfen; P K Sneed; W M Wara; D A Larson; T L Phillips; M D Prados; K A Weaver; M Malec; P Acord; K R Lamborn
Related Documents :
11823699 - Intratumoral doxorubicin in patients with malignant brain gliomas.
14654909 - Thalidomide prolongs disease stabilization after conventional therapy in patients with ...
16739319 - A randomized phase iii study: comparison between intravenous and intraarterial acnu adm...
7552809 - Concomitant chemoradiotherapy, neutron boost, and adjuvant chemotherapy for anaplastic ...
8916349 - Value of surgical intervention in the treatment of glioma.
8120569 - Localized proton spectroscopy of inoperable brain gliomas. response to radiation therapy.
15244179 - Thermic ablation with rf of liver metastases from colorectal cancer.
7996869 - Inv(16) may be one of the only 'favorable' factors in acute myeloid leukemia: a report ...
7746409 - Age influences chemotherapy response in astrocytomas.
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  International journal of radiation oncology, biology, physics     Volume:  24     ISSN:  0360-3016     ISO Abbreviation:  Int. J. Radiat. Oncol. Biol. Phys.     Publication Date:  1992  
Date Detail:
Created Date:  1992-12-14     Completed Date:  1992-12-14     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7603616     Medline TA:  Int J Radiat Oncol Biol Phys     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  583-91     Citation Subset:  IM    
Affiliation:
Department of Radiation Oncology, University of California, San Francisco 94143-0226.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Brachytherapy*
Brain Neoplasms / mortality,  radiotherapy*,  surgery
Combined Modality Therapy
Glioma / mortality,  radiotherapy*,  surgery
Humans
Iodine Radioisotopes / administration & dosage*,  adverse effects,  therapeutic use
Middle Aged
Neoplasm Recurrence, Local
Reoperation
Statistics as Topic
Survival Analysis
Grant Support
ID/Acronym/Agency:
CA 13525/CA/NCI NIH HHS; CA 39468/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Iodine Radioisotopes

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Empty sella syndrome associated with partial hypopituitarism (visualized on MRI scan).
Next Document:  Interstitial brachytherapy for newly diagnosed patients with malignant gliomas: the UCSF experience.